A5070592813- Colorectal Cancer Treatments and Studies
- Chemotherapy-related skin toxicity
- Cutaneous lymphoproliferative disorders research
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Nonmelanoma Skin Cancer Studies
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Autoimmune Bullous Skin Diseases
- Melanoma and MAPK Pathways
- Drug-Induced Adverse Reactions
- Cancer and Skin Lesions
- Cancer Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- CNS Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Pharmacovigilance and Adverse Drug Reactions
- Eosinophilic Disorders and Syndromes
- Inflammatory Myopathies and Dermatomyositis
- Histiocytic Disorders and Treatments
- Oral Health Pathology and Treatment
- Acute Myeloid Leukemia Research
- T-cell and B-cell Immunology
- Autoimmune and Inflammatory Disorders
- Cutaneous Melanoma Detection and Management
Stanford University
2016-2025
Palo Alto University
2021-2024
RELX Group (United States)
2023
Stanford Medicine
2016-2021
Kaiser Permanente
2021
Stanford Health Care
2015-2021
ORCID
2021
Advanced Dermatology
2017
University Medical Center
2016
University Hospital and Clinics
2016
Abstract Most cellular ubiquitin signaling is initiated by UBA1, which activates and transfers to tens of E2 enzymes. Clonally acquired UBA1 missense mutations cause an inflammatory-hematologic overlap disease called VEXAS (vacuoles, E1, X-linked, autoinflammatory, somatic) syndrome. Despite extensive clinical investigation into this lethal disease, little known about the underlying molecular mechanisms. Here, dissecting VEXAS-causing mutations, we discovered that p.Met41 alter cytoplasmic...
The Dark Side of Langerhans Cells Several immune cell populations reside in the skin and are thought to provide a protective barrier against infections act as sentinels malignant transformation. However, studies mice that lack cells, subset dendritic have suggested these cells may actually promote tumorigenesis. Using mouse model squamous carcinoma, Modi et al. (p. 104 ) now reveal how transformation epithelial cells. In response carcinogen 7,12-dimethylbenz[α]anthracene (DMBA), increased...
Recent advances in the immunotherapeutic treatment of cancer have led to development multiple new directed therapies including monoclonal antibodies that block immune checkpoint T-cell receptor programmed death 1 (PD-1) and PD-1 ligand, ligand (PD-L1). Various immune-related toxicities been associated with these drugs including, most commonly, skin rashes.Five cases lichenoid dermatitis, one case mucositis lichen sclerosus, anti-PD-L1 anti-PD1 therapy were compared three biopsies...
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of severe mucocutaneous drug reaction associated with significant morbidity and mortality. A previously developed SJS/TEN-specific severity-of-illness model (Score Toxic Epidermal Necrolysis [SCORTEN]) has been reported to overestimate underestimate SJS/TEN-related in-hospital mortality in various populations.To derive risk prediction for among patients SJS/TEN compare prognostic accuracy the SCORTEN...
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence immune-related adverse events (irAEs) is on rise. Dermatologic (D-irAEs) are most common and earliest to manifest, often with important downstream consequences patient. Current guidelines lack clarity in terms diagnostic criteria D-irAEs. The goal this project better define D-irAE purposes identification, diagnosis, future study group diseases.The objectives were develop consensus guidance approach...
To our knowledge, there have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab.To report the cases 3 consecutive with pembrolizumab-induced KAs and their management.Case study from 2 centers pembrolizumab-treated cancer who all developed KAs.All had AK treatment clobetasol ointment intralesional triamcinolone; also underwent open superficial cryosurgery.Three cancer, men 1 woman (median age, 83 years; range 77-91 years), experienced...
Mogamulizumab is a monoclonal antibody against CCR4 approved for treatment mycosis fungoides (MF) and Sézary syndrome (SS). Mogamulizumab-associated rash (MAR) difficult to differentiate from cutaneous MF or SS, which can lead unnecessary discontinuation of drug use because concern severe reaction incorrect presumption disease relapse progression in the skin.To examine most common clinical presentations MAR patients with SS diagnostic management challenges.This retrospective case series...
Abstract Hyperglycemia and rash are expected but challenging adverse events of phosphatidylinositol-3-kinase inhibition (such as with alpelisib). Two modified Delphi panels were conducted to provide consensus recommendations for managing hyperglycemia in patients taking alpelisib. Experts rated the appropriateness interventions on a 1-to-9 scale; median scores dispersion used classify levels agreement. Per panel, it is appropriate start alpelisib HbA1c 6.5% (diabetes) <8%, or at highest...
Rash is one of the most common adverse events observed with mogamulizumab, an anti-C-C chemokine receptor 4 monoclonal antibody approved for previously treated mycosis fungoides (MF) and Sezary syndrome (SS). Given nonspecific clinical presentations this rash, histopathologic distinction from MF/SS critical informing management. We performed a comprehensive characterization findings in mogamulizumab-associated rash (MAR) integration high-throughput sequencing T-cell (TCR) genes. Fifty-two...
Adverse drug reactions (ADRs) occur in nearly all patients on chemotherapy, causing morbidity and therapy disruptions. Detection of such ADRs is limited clinical trials, which are underpowered to detect rare events. Early recognition the postmarketing phase could substantially reduce decrease societal costs. Internet community health forums provide a mechanism for individuals discuss real-time concerns can enable computational detection ADRs.The goal this study identify cutaneous ADR signals...
Patient outcomes are improved when dermatologists provide inpatient consultations. Inpatient access to is limited, illustrating an opportunity use teledermatology. Little known about the ability of accurately diagnose disease and manage inpatients with teledermatology, particularly using nondermatologist-generated clinical data.This prospective study assessed teledermatology 41 dermatology consultations from a large urban tertiary care center, internal medicine referral documentation...
Importance Previous studies have suggested that radiation therapy may contribute to an increased risk of subsequent nonkeratinocyte (ie, not squamous and basal cell) skin cancers. Objective To test the hypothesis for breast cancer increases cancers, particularly when these cancers are localized or trunk. Design, Setting, Participants This population-based cohort study used longitudinal data from Surveillance, Epidemiology, End Results (SEER) Program January 1, 2000, December 31, 2019. The...
The US health care system generates substantial global waste. Skin biopsies are frequently performed by dermatologists and represent a practical scalable opportunity for waste reduction interventions in dermatology clinics.